Immune tolerance in haemophilia: The long journey to the fork in the road

British Journal of Haematology

Volumn 159, Issue 2, 2012, Pages 123-134

  Dimichele, Donna M ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Gene transfer; Haemophilia A; Haemophilia B; Immune modulation; Immune tolerance; Inhibitors

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 INHIBITOR; BLOOD CLOTTING FACTOR 9 INHIBITOR; BLOOD CLOTTING INHIBITOR; HOST FACTOR; IMMUNOLOGIC AGENT; RITUXIMAB; UNCLASSIFIED DRUG;

ALLERGIC REACTION; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; BLEEDING; CLINICAL PRACTICE; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; HEADACHE; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; LOW DRUG DOSE; NAUSEA; NEPHROTIC SYNDROME; NONHUMAN; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RACE DIFFERENCE; REVIEW; SERUM SICKNESS; TREATMENT OUTCOME;

ANTIBODY FORMATION; AUTOANTIBODIES; BLOOD COAGULATION FACTOR INHIBITORS; FACTOR IX; HEMOPHILIA A; HEMOPHILIA B; HUMANS; IMMUNE TOLERANCE;

EID: 84866863644     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12028     Document Type: Review

References (112)

1. Ashrani, A.A., Reding, M.T., Shet, A., Osip, J., Humar, A., Lake, J.R. & Key, N.S. (2004) Successful liver transplantation in a patient with severe hemophilia A and a high titer factor VIII inhibitor. Haemophilia, 10, 735-737.
2. Astermark, J., Morado, M., Rocino, A., Vandenberg, H.M., Von Depka, M., Gringeri, A., Mantovani, L., Garrido, R.P., Schiavoni, M., Villar, A. & Windyga, J. (2006a) Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors. Haemophilia, 12, 363-371.
3. Astermark, J., Oldenburg, J., Pavlova, A., Berntorp, E. & Lefvert, A.K. (2006b) Polymorphisms in the IL-10 but not in the IL-1β and IL-4 genes are associated with inhibitor development in patients with hemophilia A. Blood, 107, 3167-3172.
4. Astermark, J., Oldenburg, J., Carlson, J., Pavlova, A., Kavakli, K., Berntorp, E. & Lefvert, A.K., for the MIBS Study Group. (2006c) Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A. Blood, 108, 3739-3745.
5. Barnes, C., Rivard, G.E., Poon, M.C., Teitel, J., Pai, M., Kern, M., Blanchette, V.S. & Carcao, M. (2006) Inhibitor Subcommittee of Association of Hemophilia Clinic Directors of Canada. Canadian multi-institutional survey of immune tolerance therapy (ITT) -experience with the use of recombinant factor VIII for ITT. Haemophilia, 12, 1-6.
6. Barnes, C., Davis, A., Furmedge, J., Egan, B., Donnan, L. & Monagle, P. (2010) Induction of immune tolerance using rituximab in a child with severe haemophilia B with inhibitors and anaphylaxis to factor IX. Haemophilia, 16, 840-841.
7. Batlle, J., Lopez, M.F., Brackmann, H.H., Gaillard, S., Goudemand, J., Humbert, J., De Mooerloose, P., Maass, E., Mauz-Korholz, C., Sultan, Y. & Stieltjes, N. (1999) Induction of immune tolerance with recombinant factor VIII in hemophilia A patients with inhibitors. Haemophilia, 5, 431-435.
8. Benson, G., Auerswald, G., Elezović, I., Lambert, T., Ljung, R., Morfini, M., Remor, E. & Salek, S.Z. (2012) Immune tolerance induction in patients with severe hemophilia with inhibitors: expert panel views and recommendations for clinical practice. European Journal of Haematology, 88, 371-379.
9. Berntorp, E., Astermark, J. & Carlborg, E. (2000) Immune tolerance induction and the treatment of hemophilia. Malmö protocol update. Haematologica, 85(Suppl. 10), 48-50.
10. Bidlingmaier, C., Kurnik, K., Escuriola-Ettinghausen, C., Jager, R., Klamroth, R., Male, C., Marosi, A., Nemes, L., Von Stackelberg, A. & Kreuz, W. (2011) Immune tolerance induction with a factor VIII concentrate containing von Willebrand factor (Haemoctin SDH) in 14 patients with severe haemophilia A. Haemophilia, 17, e831-e848.
11. Brackmann, H.H. (1984) Induced immunotolerance in factor VIII inhibitor patients. Progress Clinical Biological Research, 150, 181-195.
12. Brackmann, H.H. & Gormsen, J. (1977) Massive factor-VIII infusion in hemophiliac with factor-VIII inhibitor, high responder. Lancet, 2, 933.
13. Brackmann, H.H., Oldenburg, J. & Schwaab, R. (1996) Immune tolerance for the treatment of factor VIII inhibitors-twenty years of the 'Bonn protocol'. Vox Sanguinis, 70(Suppl. 1), 30-35.
14. Bray, G.L., Gomperts, E.D., Courter, S., Gruppo, R., Gordon, E.M., Manco-Johnson, M., Shapiro, A., Scheibel, E., White, G. III & Lee, M. (1994) A multicenter study of recombinant factor VIII (Recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group. Blood, 83, 2428-2435.
15. Callaghan, M.U., Rajpurkar, M., Chitlur, M., Warrier, I. & Lusher, J. (2010) Immune tolerance in 31 children with haemophilia A: is ITI less successful in African Americans? Haemophilia, 17, 1365-2516.
16. Cao, O., Loduca, P.A. & Herzog, R.W. (2009) Role of regulatory T cells in tolerance to coagulation factors. Journal of Thrombosis and Haemostasis, 7(Suppl. 1), 88-91.
17. Carson, K.R., Evens, A.M., Richey, E.A., Habermann, T.M., Focosi, D., Seymour, J.F., Laubach, J., Bawn, S.D., Gordon, L.I., Winter, J.N., Furman, R.R., Vose, J.M., Zelenetz, A.D., Mamtani, R., Raisch, D.W., Dorshimer, G.W., Rosen, S.T., Muro, K., Gottardi-Little, N.R., Talley, R.L., Sartor, O., Green, D., Major, E.O. & Bennett, C.L. (2009) Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood, 113, 4834-4840.
18. Chambost, H. (2010) Assessing risk factors: prevention of inhibitors in haemophilia. Haemophilia, 16(Suppl. 2), 10-15.
19. Chitlur, M., Warrier, I., Raipurkar, M. & Lusher, J.M. (2009) Inhibitors in factor IX deficiency a report of the ISTH-SSC international FIX inhibitor registry (1997-2006). Haemophilia, 15, 1027-1031.
20. Christophe, O.D., Lenting, P.J., Cherel, G., Boon-Spijker, M., Lavergne, J.M., Boertjes, R., Briquel, M.E., de Goede-Bolder, A., Goudemand, J., Gaillard, S., d'Oiron, R., Meyer, D. & Mertens, K. (2001) Functional mapping of anti-factor IX inhibitors developed in patients with severe haemophilia B. Blood, 98, 1416-1423.
21. Chuansumrit, A., Moonsup, Y., Sirachainan, N., Benjaponpitak, S., Suebsangad, A. & Wongwerawattanakoon, P. (2008) The use of rituximab as an adjuvant for immune tolerance therapy in a hemophilia B boy with inhibitor and anaphylaxis to factor IX concentrate. Blood Coagulation & Fibrinolysis, 19, 208-211.
22. Collins, P. (2006) Novel Therapies for Immune Tolerance in Hemophilia A. Haemophilia, 12(Suppl. 6), 94-101.
23. Collins, P.W., Mathias, M., Hanley, J., Keeling, D.M., Keenan, R., Laffan, M., Perry, D. & Liesner, R. (2009) Rituximab and immune tolerance in severe hemophilia A: a consecutive national cohort. Journal of Thrombosis and Haemostasis, 7, 787-794.
24. Cooper, M., Nayak, S., Hoffman, B., Terhorst, C., Ca, O. & Herzog, R.W. (2009) Improved Induction of Immune Tolerance to Factor IX by Hepatic AAV-8 Gene Transfer. Human Gene Therapy, 20, 767-776.
25. Coppola, A., Margaglione, M., Santagostino, E., Rocino, A., Grandone, E., Mannucci, P.M. & DiMinno, G. (2009) Factor VIII gene (F8) mutations as predictors of outcome in immune tolerance induction of hemophilia A patients with high-responding inhibitors. Journal of Thrombosis and Haemostasis, 7, 1809-1815.
26. Coppola, A., DiMinno, M.N. & Santagostino, E. (2010) Optimizing management of immune tolerance induction in patients with severe haemophilia A and inhibitors: towards evidence-based approaches. British Journal of Haematology, 150, 515-528.
27. Courter, S.G. & Bedrosian, C.L. (2001) Clinical evaluation of B-domain deleted recombinant factor VIII in previously untreated patients. Seminars in Hematology, 38, 52-59.
28. Cross, D.C. & Van Der Berg, H.M. (2007) Cyclosporin A can achieve immune tolerance in a patient with severe haemophilia B and refractory inhibitors. Haemophilia, 13, 111-114.
29. Di Minno, G. & Coppola, A. (2011) A role for von Willebrand factor in immune tolerance induction in patients with haemophilia A and inhibitors? Blood Transfusion, 9(Suppl. 2), s14-s20.
30. DiMichele, D. (2007) Inhibitor development in haemophilia B: an orphan disease in need of attention. British Journal of Haematology, 138, 305-315.
31. DiMichele, D.M. (2011) Immune tolerance induction in haemophilia; evidence and the way forward. Journal of Thrombosis and Haemostasis, 9(Suppl. 1), 216-225.
32. DiMichele, D.M. & Kroner, B. and the North American Immune Tolerance Study Group. (2002) The North American Immune Tolerance Registry: practices, outcomes, outcome predictors. Thrombosis and Haemostasis, 87, 52-57.
33. DiMichele, D.M., Hoots, W.K., Pipe, S.W., Rivard, G.E. & Santagostino, E. (2007) International workshop on immune tolerance induction: consensus recommendations. Haemophilia, 13(Suppl. 1), 1-22.
34. Dobrzynski, E., Fitzgerald, J.H., Cao, O., Mingozzi, F., Wang, L. & Hertzog, R.W. (2006) Prevention of cytotoxic T lymphocyte responses to factor IX-expressing hepatocytes by gene transfer-induces regulatory T cells. Proceedings National Academy Sciences USA, 103, 4592-4597.
35. D'Oiron, R., Pipe, S.W. & Jacquemin, M. (2008) Mild/moderate haemophilia A: new insights into molecular mechanisms and inhibitor development. Haemophilia, 14(Suppl. 3), 138-146.
36. Ettinger, R.A., James, E.A., Kwok, W.W., Thompson, A.R. & Pratt, K.P. (2009) Lineages of human T-cell clones, including T helper 17/T helper 1 cells, isolated at different stages of anti-factor VIII immune responses. Blood, 114, 1423-1428.
37. Ettingshausen, C.E. & Kreuz, W. (2005) Role of von Willebrand factor in immune tolerance induction. Blood Coagulation & Fibrinolysis, 16(Suppl. 1), s27-s31.
38. Ewenstein, B.M., Takemoto, C., Warrier, I., Lusher, J., Saidi, P., Eisele, J., Ettinger, E.J. & DiMichele, D. (1997) Nephrotic syndrome as a complication of immune tolerance in hemophilia B. Blood, 89, 1115-1116.
39. Ewenstein, B.M., Valentino, L.A., Journeycake, J.M., Tarantino, M.D., Shapiro, A.D., Blanchette, V.S. & Hoots, W.K. (2004) Consensus recommendations for use of central venous access devices in hemophilia. Haemophilia, 10, 629-648.
40. Finn, J.D., Ozelo, M.C., Sabatino, D.E., Franck, H.W., Merricks, E.P., Crudele, J.M., Zhou, S., Kazazian, H.H., Lillicrap, D., Nicols, T.C. & Arruda, V.R. (2010) Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy. Blood, 116, 5842-5848.
41. Fox, R.A., Neufeld, E.J. & Bennett, C.M. (2006) Rituximab for adolescents with haemophilia and high titre inhibitors. Haemophilia, 12, 218-222.
42. Franchini, M., Veneri, D., Lippi, G. & Stenner, R. (2006) The efficacy of rituximab in the treatment of inhibitor-associated hemostatic disorders. Thrombosis and Haemostasis, 96, 119-125.
43. Franchini, M., Mengoli, C., Lippi, G., Targher, G., Montagnana, M., Salvagno, G.L., Zaffanello, M. & Cruciani, M. (2008) Immune tolerance with rituximab in congenital hemophilia with inhibitors: a systematic literature review based on individual patients' analysis. Haemophilia, 14, 903-912.
44. Franchini, M., Favaloro, E.J. & Lippi, G. (2009) Mild Hemophilia A. Journal of Thrombosis and Haemostasis, 8, 421-432.
45. Freiburghaus, C., Berntorp, E., Ekman, M., Gunnarsson, M., Kjellberg, B.M. & Nilsson, I.M.T. (1999) Tolerance induction using the Malmö treatment model 1982-1995. Haemophilia, 5, 32-39.
46. Gaitonde, P., Peng, A., Straubinger, R.M., Bankert, R.B. & Balu-lyer, S.V. (2010) Phosphatidylserine reduces immune response against human recombinant Factor VIII in Hemophilia A mice by regulation of dendritic cell function. Clinical immunology, 138, 135-145.
47. Gilles, J.G. (2010) Role of anti-idiotypic antibodies in immune tolerance induction. Haemophilia, 16, 80-83.
48. Greenwood, R., Wang, B., Midkiff, K., White, G.C., Lin, H.F. & Frelinger, J.A. (2003) Identification of T-cell epitopes in clotting factor IX and lack of tolerance in inbred mice. Journal of Thrombosis and Haemostasis, 1, 95-102.
49. Greninger, D.A., Saint-Remy, J.M., Jacquemin, M., Benhida, A. & DiMichele, D.M. (2008) The use of factor VIII/von Willebrand factor concentrate for immune tolerance induction in haemophilia A patients with high-titre inhibitors: association of clinical outcome with inhibitor epitope profile. Haemophilia, 14, 295-302.
50. Gringeri, A., Musso, R., Mazzucconi, M.G., Piseddu, G., Schiavoni, M., Pignoloni, P. & Mannucci, P.M. (2007a) Immune tolerance induction with a high purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response. Haemophilia, 13, 373-379.
51. Gringeri, A. (2007b) VWF/FVIII concentrates in high risk immunotolerance: the RESIST study. Haemophilia, 13(Suppl. 5), 73-77.
52. Gruppo, R.A., Valdez, L.P. & Stout, R.D. (1992) Induction of immune tolerance in patients with hemophilia A and inhibitors. The American journal of pediatric hematology/oncology, 14, 82-87.
53. Hay, C.R. & DiMichele, D.M. (2012) The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood, 119, 1335-1344.
54. Hay, C.R., Ludlam, C.A., Colvin, B.T., Hill, F.G., Preston, F.E., Wasseem, N., Bagnall, R., Peake, I.R., Berntorp, E., Mauser Bunschoten, E.P., Fijnvandraat, K., Kasper, C.K., White, G. & Santagostino, E. (1998) Factor VIII inhibitors in mild and moderate-severity hemophilia A. UK Hemophilia Centre Directors Organisation. Thrombosis and Haemostasis, 79, 762-766.
55. Hay, C.R.M., Brown, S., Collins, P.W., Keeling, D.M. & Liesner, R. (2006) The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Centre Doctors Organisation. British Journal of Haematology, 133, 591-605.
56. Hay, C.R., Palmer, B., Chalmers, E., Leisner, R., Maclean, R., Rangarajan, S., Williams, M. & Collins, P.W., United Kingdom Haemophilia Centre Doctors' Organisation (UKHCDO). (2011) The incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom. Blood, 117, 6367-6370.
57. van Helden, P.M., Van Haren, S.D., Fijnvandraat, K., van den Berg, H.M. & Voorberg, J. (2010) Factor VIII-specific B cell responses in haemophilia A patients with inhibitors. Haemophilia, 16, 35-43.
58. van Helden, P.M., Unterthurner, S., Hermann, C., Schuster, M., Ahmad, R.U., Schiviz, A.N., Weiller, M., Antoine, G., Turecek, P.L., Muchitsch, E.M., Schwarz, H.P. & Reipert, B.M. (2011) Maintenance and break of immune tolerance against human factor VIII in a new transgenic hemophilic mouse model. Blood, 118, 3698-3707.
59. Hu, C., Cela, R.G., Suzuki, M., Lee, B. & Lipshutz, G.S. (2010) Neonatal helper-dependent adenoviral vector gene therapy mediates correction of hemophilia A and tolerance to human factor VIII. Proceedings National Academy Sciences USA, 108, 2082-2087.
60. Irigoyen, M.B., Felippo, M.E., Primiani, L., Candela, M., Bianco, R.P., de Bracco, M.M. & Galassi, N. (2012) Severe haemophilia A patients have reduced numbers of peripheral memory B cells. Haemophilia, 18, 437-443.
61. Kallas, A., Kuuse, S., Maimets, T. & Pooga, M. (2010) Naturally occurring CD4 + CD25 + cells in modulating immune response to administered coagulation factor VIII in factor VIII-deficient mice. Haemophilia, 17, 143-151.
62. Kelly, M.E., Zhou, J., Bharadwaj, A.S. & Chao, H. (2009) Induction of immune tolerance to FIX following muscular AAV gene transfer is AAV-dose/FIX-level dependent. Molecular Therapy, 17, 857-863.
63. Kempton, C.L., Soucie, J.M., Miller, C.H., Hooper, C., Escobar, M.A., Cohen, A.J., Key, N.S., Thompson, A.R. & Abshire, T.C. (2010) In non-severe hemophilia A the risk of inhibitor after intensive factor treatment is greater in older patients: a case-control study. Journal of Thrombosis and Haemostasis, 8, 224-231.
64. Kessel, C., Konigs, C., Linde, R., Escuriola-Ettinghausen, C., Stoll, H., Klingebiel, T., Dietrich, U. & Kreuz, W. (2008) Humoral immune responsiveness to a definite epitope on factor VIII before and after B cell ablation with rituximab. Molecular Immunology, 46, 8-15.
65. Klarmann, D., Martines Saguer, I., Funk, M.B., Knoefler, R., von Hentig, N., Heller, C. & Kreuz, W. (2008) Immune tolerance induction with mycophenolate-mofetil in two children with haemophilia B and inhibitor. Haemophilia, 14, 44-49.
66. Kreuz, W. (2008) The role of VWF for the success of immune tolerance induction. Thrombosis Research, 122(Suppl. 2), S7-S12.
67. Kroner, B.L. (1999) Comparison of the International Immune Tolerance Registry and the North American Immune Tolerance Registry. Vox Sanguinis, 77(Suppl. 1), 33-37.
68. Kurth, M.A., Dimichele, D., Sexauer, C., Sanders, J.M., Torres, M., Zappa, S.C., Ragni, M. & Leonard, N. (2008) Immune tolerance therapy utilizing factor VIII/von Willebrand factor concentrate in haemophilia A patients with high titre factor VIII inhibitors. Haemophilia, 14, 50-55.
69. Lenk, H. (2000) ITT Study Group. The German Registry of immune tolerance treatment in hemophilia-1999 update. Haematologica, 85(Suppl. 10), 45-47.
70. Lin, H.F., Maeda, N., Smithies, O., Straight, D.L. & Stafford, D.W. (1997) A coagulation factor IX-deficient mouse model for human hemophilia B. Blood, 90, 3962-3966.
71. Lollar, P. (2005) Pathogenic antibodies to coagulation factors. Part one: factor VIII and factor IX. Journal of Thrombosis and Haemostasis, 2, 1082-1095.
72. Lozier, J.N., Tayebi, N. & Zhang, P. (2005) Mapping of genes that control the antibody response to human factor IX in mice. Hemostasis, Thrombosis, and Vascular Biology, 105, 1029-1035.
73. Lusher, J.M. (1994) Summary of clinical experience with recombinant factor VIII products-Kogenate. Annals of Hematology, 68(Suppl. 3), S3-S6.
74. Mancuso, M.E. & Berardinelli, L. (2010) Arteriovenous fistula as stable venous access in children with severe haemophilia. Haemophilia, 16(Suppl. 1), 25-28.
75. Mariani, G. & Kroner, B. (2001) Immune tolerance in hemophilia with factor VIII inhibitors: predictors of success. Haematologica, 86, 1186-1993.
76. Mariani, G., Scheibel, E., Nogao, T., Kasper, C.K., Ewing, N.P., Mauser-Bunschoten, E., Ghirardini, A., Bellocco, R. & Brackmann, H.H. (1994) Immunetolerance as treatment of alloantibodies to factor VIII in hemophilia. The International Registry of Immunetolerance Protocols. Seminars in hematology, 31, 62-64.
77. Mariani, G., Siragusa, S. & Kroner, B.L. (2003) Immune tolerance induction in hemophilia A: a review. Seminars in Thrombosis and Hemostasis, 29, 69-76.
78. Mathias, M., Khair, K., Hann, I. & Liesner, R. (2004) Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe hemophilia. British Journal of Haematology, 125, 366-368.
79. Matsui, H., Shibata, M., Brown, B., Labelle, A., Hegadorn, C., Andrews, C., Chuah, M., VandenDriessche, T., Miao, C.H., Hough, C. & Lillicrap, D. (2009) A murine model for induction of long-term immunologic tolerance to factor VIII does not require persistent detectable levels of plasma factor VIII and involves contributions from Foxp3 + T regulatory cells. Blood, 114, 677-685.
80. Mauser-Bunschoten, E.P., Rosendaal, F.R., Nieuwenhuis, H.K., Roosendaal, G., Briet, E. & van den Berg, H.M. (1994) Clinical course of factor VIII inhibitors developed after exposure to a pasteurized Dutch concentrate compared to classic inhibitors in hemophilia A. Thrombosis and Haemostasis, 71, 703-706.
81. Mingozzi, F., Liu, Y.L., Dobrzynski, E., Kaufhold, A., Liu, J.H., Wang, Y., Arruda, V.R., High, K.A. & Herzog, R.W. (2003) Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer. Journal of Clinical Investigation, 111, 1347-1356.
82. Nayak, S., Cao, O., Hoffman, B.E., Cooper, M., Zhou, S., Atkinson, M.A. & Herzog, R.W. (2009) Prophylactic immune tolerance induced by changing the ratio of antigen-specific effector to regulatory T cells. Journal of Thrombosis and Haemostasis, 7, 1523-1532.
83. Nilsson, I.M., Berntorp, E. & Zetterval, O. (1986) Induction of split tolerance and clinical cure in high-responding hemophiliacs with factor IX antibodies. Proceedings National Academy Sciences USA, 83, 9169-9173.
84. Nilsson, I.M., Berntorp, E. & Zettervall, O. (1988) Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII. New England Journal of Medicine, 318, 947-950.
85. Orsini, F., Rotschild, C., Beurrier, P., Faradji, A., Goudemand, J. & Polack, B. (2005) Immune tolerance induction with highly purified plasma-derived factor VIII containing von Willebrand factor in hemophilia A patients with high-responding inhibitors. Haematologica, 90, 1288-1290.
86. Pautard, B., D'Oiron, R., Li Thiao Te, V., Lavend'homme, R., Saint-Remy, J.M., Peerlinck, K. & Jacquemin, M. (2011) Successful immune tolerance induction by FVIII in hemophilia A patients with inhibitor may occur without deletion of FVIII-specific T cells. Journal of Thrombosis and Haemostasis, 9, 1163-1170.
87. Pipe, S.W. (2005) The promise and challenges of bioengineered recombinant clotting factors. Journal of Thrombosis and Haemostasis, 3, 1692-1701.
88. Qadura, M., Waters, B., Burnett, E., Chegeni, R., Hough, C., Othman, M. & Lillicrap, D. (2011) Immunoglobin isotypes and functional anfi-FVIII antibodies in response to FVIII treatment in Balb/c and C57BL/6 haemophilia A mice. Haemophilia, 17, 288-295.
89. Reipert, B.M., van den Helden, P.M., Schwarz, H.P. & Hausl, C. (2007) Mechanisms of action of immune tolerance induction against factor VIII in patients with congenital hemophilia A and factor VIII inhibitors. British Journal of Haematology, 136, 2-25.
90. Reipert, B.M., Allacher, P., Hausl, C., Pordes, A.G., Ahmad, R.U., Lang, I., Ilas, J., Windyga, J., Klukowska, A., Muchitsch, E.M. & Schwarz, H.P. (2010a) Modulation of factor VIII-specific memory B cells. Haemophilia, 16, 25-34.
91. Reipert, B., Arruda, V. & Lillicrap, D. (2010b) Animal models of inhibitors. Haemophilia, 16(Suppl. 5), 47-53.
92. Rivard, G.E., St. Louis, J., Lacroix, S., Champagne, M. & Rock, G. (2003) Immunoadsorption for coagulation factor inhibitors: a retrospective critical appraisal of 10 consecutive cases from a single institution. Haemophilia, 71, 1-716.
93. Robbins, D., Kulkarni, R., Gera, R., Scott-Emuakpor, A.B., Bosma, K. & Penner, J.A. (2001) Successful treatment of high titer inhibitors in mild hemophilia A with avoidance of factor VIII and immunosuppressive therapy. American Journal of Hematology, 68, 184-188.
94. Rocino, A., Papa, M.L., Salerno, E., Capasso, F., Miraglia, E. & deBiasi, R. (2001) Immune tolerance induction in hemophilia A patients with high-responding inhibitors to factor VIII: experience at a single institution. Haemophilia, 7, 33-38.
95. Rocino, A., Santagostino, E., Mancuso, M.E. & Mannucci, P.M. (2006) Immune tolerance induction with recombinant factor VIII in hemophilia A patients with high responding inhibitors. Haematologica, 91, 558-561.
96. Sakurai, Y., Matsutanit, T., Yoshioka, T., Takeda, T., Yoshioka, A. & Shima, M. (2011) Alterations of T cell receptor Vbeta repertoire of CD8 T lymphocytes in immune tolerance induction in two hemophilia A patients with inhibitors. Vojnosanitetski Pregled, 68, 1047-1050.
97. Santagostino, E., Gringeri, A., Tagliavacca, L. & Mannucci, P.M. (1995) Inhibitors to factor VIII in a family with mild hemophilia: molecular characterization and response to factor VIII and desmopressin. Thrombosis and Haemostasis, 74, 619-621.
98. Santagostino, E., Auerswald, G., Jimenez-Yuste, V., Ljung, R., Morfini, M., Rocino, A. & Young, G. (2010) European initiative to prevent joint damage in hemophilia children with inhibitors (ENJOIH)- a prospective study. Haemophilia, 16, 407.
99. Sawamoto, Y., Shima, M., Yamamoto, M., Kamisue, S., Nakai, H., Tanaka, I., Hayashi, K., Giddings, J.C. & Yoshioka, A. (1996) Measurement of anti-factor IX IGG subclasses in haemophilia B patients who developed inhibitors with episodes of allergic reactions to factor IX concentrates. Thrombosis Research, 83, 279-286.
100. Scott, D.A. (2010) Gene therapy for immunological tolerance: using "transgenic" B cells to treat inhibitor formation. Haemophilia, 16, 89-94.
101. Scott, D.W. & Lozier, J.N. (2011) Gene therapy for haemophilia: prospects and challenges to prevent or reverse inhibitor formation. British Journal of Haematology, 156, 295-302.
102. Smith, M.P., Spence, K.J., Waters, E.L., Beresford-Webb, R., Mitchell, M.J., Cuttler, J., Alhaq, A., Brown, S.A. & Savidge, G.F. (1999) Immune tolerance therapy for hemophilia A patients with acquired factor VIII alloantibodies: comprehensive analysis of experience at a single institution. Thrombosis and Haemostasis, 81, 35-38.
103. Sperr, W.R., Lechner, K. & Pabinger, I. (2007) Rituximab for the treatment of acquired antibodies to factor VIII. Haematologica, 92, 66-71.
104. Stachnik, J.M. (2006) Rituximab in the treatment of acquired hemophilia. The Annals of pharmacotherapy, 40, 1151-1157.
105. Su, R.J., Epp, A., Latchman, Y., Bolgiano, D., Pipe, S.W. & Josephson, N.C. (2009) Suppression of FVIII inhibitor formation in hemophilic mice by delivery of transgene modified apoptotic fibroblasts. Molecular Therapy, 18, 214-222.
106. Su, R.J., Epp, A., Fend, J., Roy, J., Latchman, Y., Wu, X., Bolgiano, D. & Josephson, N.C. (2011) Suppression of the immune response to FVIII in hemophilia A mice by transgene modified tolerogenic dendritic cells. Molecular Therapy, 10, 1896-1904.
107. Sule, G., Suzuki, M., Guse, K., Cela, R., Rodgers, J.R. & Lee, B. (2012) Cytokine-conditioned dendritic cells induce humoral tolerance to protein therapy in mice. Human Gene Therapy. 23, 769-780.
108. Uprichard, J., Dazzi, F., Apperley, J.F. & Laffan, M.A. (2009) Haemopoietic stem cell transplantation induces tolerance to donor antigens but not to foreign FVIII peptides. Haemophilia, 16, 143-147.
109. Vlot, A.J., Wittebol, S., Strengers, P.F., Turenhout, E.A., Voorberg, J., van den Berg, H.M. & Mauser-Bunschoten, E.P. (2002) Factor VIII inhibitor in a patient with mild hemophilia A and an Asn618->Ser mutation responsive to immune tolerance induction and cyclophosphamide. British Journal of Haematology, 117, 136-140.
110. Waters, B. & Lillicrap, D. (2009) The molecular mechanisms of immunomodulation and tolerance induction to factor VIII. Journal of Thrombosis and Haemostasis, 7, 1446-1456.
111. Wermes, C., von Depka Prondzinski, M., Welte, K. & Sykora, K.-W. (2000) New strategy for the treatment of factor IX inhibitors in severe haemophilia B. Blood, 96, 267a.
112. Zhang, A.H., Skupsky, J. & Scott, D.W. (2010) Effect of B-cell depletion using anti-CD20 therapy on inhibitory formation to human FVIII in hemophilia A mice. Blood, 117, 2223-2226.